Brendan A. Larder
#163,619
Most Influential Person Now
Brendan A. Larder's AcademicInfluence.com Rankings
Brendan A. Larderbiology Degrees
Biology
#13112
World Rank
#16639
Historical Rank
Virology
#322
World Rank
#329
Historical Rank
Microbiology
#807
World Rank
#886
Historical Rank
Neuroscience
#2255
World Rank
#2316
Historical Rank
Download Badge
Biology
Brendan A. Larder's Degrees
- PhD Microbiology University of California, Berkeley
- Bachelors Biology University of California, Berkeley
Similar Degrees You Can Earn
Why Is Brendan A. Larder Influential?
(Suggest an Edit or Addition)Brendan A. Larder's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. (1989) (1515)
- Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). (1989) (1178)
- Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. (1995) (655)
- Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. (1991) (622)
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. (1993) (599)
- Mutations in Retroviral Genes Associated with Drug Resistance (1996) (441)
- Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. (1992) (428)
- A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs (1998) (405)
- Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. (1992) (378)
- Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. (1991) (288)
- Site-specific mutagenesis of AIDS virus reverse transcriptase (1987) (275)
- Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure (2000) (248)
- 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors (1992) (244)
- Genotypic Correlates of Phenotypic Resistance to Efavirenz in Virus Isolates from Patients Failing Nonnucleoside Reverse Transcriptase Inhibitor Therapy (2001) (242)
- Related functional domains in virus DNA polymerases. (1987) (218)
- Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates (1994) (208)
- Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay (1990) (202)
- Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing (1993) (194)
- Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples (2000) (192)
- A Family of Insertion Mutations between Codons 67 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Multinucleoside Analog Resistance (1999) (188)
- Relative Replicative Fitness of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Isolates In Vitro (1998) (184)
- Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy (1990) (176)
- Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro (1993) (164)
- Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. (2000) (163)
- Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples (2000) (160)
- Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance (1995) (156)
- Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture (1991) (156)
- Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. (1989) (149)
- Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. (1994) (148)
- Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. (1986) (145)
- Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. (1991) (145)
- Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture (1994) (134)
- HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis. (1988) (131)
- A Novel Polymorphism at Codon 333 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Can Facilitate Dual Resistance to Zidovudine and l-2′,3′-Dideoxy-3′-Thiacytidine (1998) (128)
- Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility (1996) (124)
- A Novel Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutational Pattern Confers Phenotypic Lamivudine Resistance in the Absence of Mutation 184V (2000) (123)
- Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel (2000) (123)
- World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing (2001) (120)
- Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. (1999) (119)
- Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine. (1992) (108)
- Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. (2003) (105)
- HIV‐1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment (1992) (103)
- Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. (1994) (101)
- Virus drug-resistance: mechanisms and consequences. (1984) (101)
- Performance of the Affymetrix GeneChip HIV PRT 440 Platform for Antiretroviral Drug Resistance Genotyping of Human Immunodeficiency Virus Type 1 Clades and Viral Isolates with Length Polymorphisms (1999) (100)
- Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen (2000) (99)
- Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure (2000) (99)
- Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir. (1989) (99)
- AIDS virus reverse transcriptase defined by high level expression in Escherichia coli. (1987) (87)
- Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. (1996) (87)
- Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. (1998) (87)
- Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. (1983) (85)
- Resistance to Nucleoside Analog Reverse Transcriptase Inhibitors Mediated by Human Immunodeficiency Virus Type 1 p6 Protein (2001) (84)
- Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. (2000) (83)
- The Development of Artificial Neural Networks to Predict Virological response to Combination HIV Therapy (2007) (83)
- HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort (2000) (77)
- Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. (1994) (76)
- Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. (2004) (76)
- The M184 V mutation in HIV‐1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross‐resistance to nucleoside analogue RT inhibitors (1998) (75)
- Viral resistance and the selection of antiretroviral combinations. (1995) (75)
- Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up (2001) (75)
- Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 (2002) (72)
- Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function (1988) (71)
- High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. (2001) (69)
- A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy (2009) (68)
- Mutational analysis of two conserved sequence motifs in HIV‐1 reverse transcriptase (1991) (67)
- Effects of Dipeptide Insertions between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain Elongation (2003) (66)
- Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215 (2002) (66)
- Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. (2002) (64)
- 3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. (1998) (63)
- Biochemical Mechanism of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistance to Stavudine (2001) (61)
- High Prevalence of Genotypic and Phenotypic HIV‐1 Drug‐Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'lvoire (2001) (59)
- Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities. (1985) (59)
- Genotypic and Phenotypic Evidence of Different Drug-Resistance Mutation Patterns between B and Non-B Subtype Isolates of Human Immunodeficiency Virus Type 1 found in Brazilian Patients Failing HAART (2004) (58)
- Correlation between Viral Resistance to Zidovudine and Resistance at the Reverse Transcriptase Level for a Panel of Human Immunodeficiency Virus Type 1 Mutants (2001) (57)
- Properties of purified enzymes induced by pathogenic drug-resistant mutants of herpes simplex virus. Evidence for virus variants expressing normal DNA polymerase and altered thymidine kinase. (1983) (56)
- Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates (1993) (55)
- A Mutation in the 3′ Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance (2002) (52)
- Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (1996) (52)
- Mutations in RT and Protease III -93 NOV 95 Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance (1996) (49)
- Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. (2000) (48)
- Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1 (2002) (47)
- Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates (2002) (46)
- Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation of Established Mutations and Characterization of New Polymorphisms at Codons 208, 211, and 214 (2003) (41)
- Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasma. (2001) (41)
- Closing in on HIV drug resistance (1999) (40)
- 11 Inhibitors of HIV Reverse Transcriptase as Antiviral Agents and Drug Resistance (1993) (39)
- Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir (1986) (38)
- Cooperative effects between two acyclovir resistance loci in herpes simplex virus (1984) (38)
- Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative – Uganda (2003) (37)
- Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance (1994) (35)
- Extent of Cross-Resistance between Agents Used To Treat Human Immunodeficiency Virus Type 1 Infection in Clinically Derived Isolates (2002) (34)
- Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings. (2013) (33)
- Non‐parametric methods to predict HIV drug susceptibility phenotype from genotype (2003) (33)
- Resistance to antiretroviral therapy among patients in Uganda. (2001) (32)
- Mechanisms of HIV-1 drug resistance. (2001) (32)
- Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings. (2010) (31)
- Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1-infected persons. (1997) (30)
- Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy. (2000) (29)
- Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. (2001) (27)
- Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant (1982) (27)
- The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool (2011) (26)
- Restoration of wild-type pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1. (1986) (25)
- Clinical evaluation of the potential utility of computational modeling as an HIV treatment selection tool by physicians with considerable HIV experience. (2011) (23)
- Sensitivity of viruses to phosphorylated 9-(2-hydroxyethoxymethyl)guanine revealed in TK-transformed cells. (1980) (23)
- Provirus load changes in untreated and zidovudine-treated human immunodeficiency virus type 1-infected patients. (1994) (20)
- Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: a prospective study. (2001) (19)
- Prevalence of genotypic and phenotypic HIV‐1 drug‐resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS–Drug Access Initiative in Abidjan, Côte d'Ivoire (2003) (18)
- Influence of naturally occurring insertions in the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and mutation frequencies in vitro. (2006) (17)
- Application of Artificial Neural Networks for Decision Support in Medicine (2009) (16)
- Isolation and characterization of acyclovir-resistant strains of herpes simplex virus. (1982) (15)
- An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes. (2014) (15)
- Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy. (2001) (14)
- The clinical significance of antiviral drug resistance. (1992) (13)
- An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. (2016) (10)
- Broad Advances in Understanding HIV Resistance to Antiretrovirals: Report on the XVII International HIV Drug Resistance Workshop (2008) (10)
- The use of computational models to predict response to HIV therapy for clinical cases in Romania. (2012) (10)
- Genotypic Correlates of Reduced In Vitro Susceptibility to ABT-378 in HIV Isolates From Patients Failing Protease Inhibitor Therapy (1999) (9)
- Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy (2002) (9)
- Clinical Implications of Resistance to Antiretrovirals: New Resistance Technologies and Interpretations (2008) (9)
- Low prevalence of antiretroviral drug resistance among HIV-1 seroconverters in London, 1984-1991. (2002) (8)
- Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors. (1989) (7)
- The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients. (1999) (7)
- Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy (2009) (6)
- Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa (2016) (6)
- The growth and characterization of crystals of human immunodeficiency virus (HIV) reverse transcriptase (1993) (6)
- Emergence and clinical relevance of mutations associated with zidovudine resistance in asymptomatic HIV-1 infected patients (1995) (6)
- Structural studies of the acquired immunodeficiency syndrome virus reverse transcriptase. (1988) (6)
- Structural Studies on Human Immunodeficiency Virus Reverse Transcriptase (1990) (5)
- THE INFLUENCE OF COMBINATION THERAPY ON HIV-1 VIRAL LOAD AND DRUG RESISTANCE (1994) (5)
- Antiviral activity of tenofovir against nucleoside-resistant HIV samples (2000) (5)
- 2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings (2018) (5)
- HIV and Hepatitis Virus Resistance to Antivirals: Review of Data from the Xix International HIV and Hepatitis Virus Drug Resistance Workshop and Curative Strategies (2011) (5)
- Potential Impact of a Free Online HIV Treatment Response Prediction System for Reducing Virological Failures and Drug Costs after Antiretroviral Therapy Failure in a Resource-Limited Setting (2013) (4)
- Key Reports from the XV International HIV Drug Resistance Workshop 2006 (2007) (3)
- Progress in Basic and Clinical Research on HIV Resistance: Report on the XVIII International HIV Drug Resistance Workshop (2009) (3)
- Anti-HIV agent 935U83 — Preliminary clinical assessment (1995) (3)
- A PLACEBO CONTROLLED TRIAL OF AZT ALONE OR IN COMBINATION WITH DDI OR DDC: VIRAL LOAD AND DRUG RESISTANCE (1994) (3)
- Tree models for the evolution of drug resistance (2003) (3)
- ANTIVIRAL POTENCY OF AZT + 3TC COMBINATION THERAPY IN VIVO SUPPORTS IN VITRO VIROLOGICAL OBSERVATIONS (1994) (2)
- Modelling response to antiretroviral therapy without a genotype as a clinical tool for resource-limited settings (2011) (2)
- Fourth International Workshop : abstracts presented at a Workshop held in Sardinia, Italy on July 6-9, 1995 (1995) (1)
- Analysis of viral isolates following viral load rebound on therapy with ABT-378/ritonavir (2000) (1)
- Modelling treatment response could reduce virological failure in different patient populations (2013) (1)
- Accurate prediction of response to HIV therapy without a genotype: a potential tool for therapy optimization in resource-limited settings (2013) (1)
- The Xivth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005 (2005) (1)
- Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response (2019) (1)
- HIV Variation: Consequences for antiviral therapy and disease progression (1995) (1)
- A method for resistance to a therapeutic agent predict using neural networks (2001) (0)
- Predicting response to HIV therapy (2014) (0)
- The development of neural networks to predict virologic response to combination HIV therapy (2007) (0)
- Viral Isolates with Length Polymorphisms Immunodeficiency Virus Type 1 Clades and Drug Resistance Genotyping of Human HIV PRT 440 Platform for Antiretroviral Performance of the Affymetrix GeneChip (1999) (0)
- Method for determination of the resistance to drug (2001) (0)
- Methods for measuring the resistance to drugs. (2001) (0)
- HIV resistance profiles in the gastrointestinal mucosa can be determined from rectosigmoid biopsies (2000) (0)
- Setting values and biological cut to predict therapy resistance. (2001) (0)
- 2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. (2021) (0)
- New progress in antiretroviral combination therapy (1995) (0)
- Fifth International Conference on AIDS : the Scientific and Social Challenge; symposium; mechanisms of pathogenesis of human retroviruses (1989) (0)
- New mutation profile of HIV-1 reverse transcriptase combined with phenotypic drug resistance (2000) (0)
- Development of a novel assay for chemosensitivity testing in vitro for primary human tumours (2001) (0)
- virus type 1 isolates. susceptibility of human immunodeficiency phenotypic assay for assessment of drug Recombinant virus assay: a rapid, (2014) (0)
- Development of novel high throughput microsatellite technology for detection of bladder cancer (2001) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Brendan A. Larder?
Brendan A. Larder is affiliated with the following schools:
